Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung disease. The International Society for Heart and Lung Transplantation (ISHLT) reports unadjusted analysis of post-transplant survival 82% for bilateral and 78% for unilateral at 1 year, and 69% and 61%, respectively, at 3-years.
unregulated proliferation as a result of calcineurin inhibitors diminishing CTL function. This proliferation of lymphocytes results in the development of PTLD. If seronegative LTRs become infected with the lytic form of the virus, immunosuppression allows for a massive amplification of the virus and infection of B cells that can lead to the development of PTLD. 15 T-cell lineage is estimated to account for around 10%-15% of PTLD cases, with 30% of cases being EBV positive. 15, 35 Of note, the prevalence of human T-cell lymphotropic viruses in some parts of the world may contribute to a higher instance of T lymphocyte PTLD, with 1 publication reporting an incidence rate as high as 40%. 35 Lastly, PTLD of the natural killer cell lineage has only been reported in occasional cases. 15, 36, 37 There remains no unified treatment approach for PTLD due to the heterogeneous and unpredictable nature of the disease, with treatments ranging from reduction in immunosuppression (RI) to the use of rituximab and/or chemotherapy. Initial RI remains the first step in treatment of all types of PTLD to control EBV-induced B-cell proliferation and regain appropriate CTL function, while also preventing allograft rejection. 18 RI treatment alone is common in the minority of PTLD patients who develop early lesions, localized polyclonal PTLD, 19 and carries a response rate lower than 50%. [18] [19] [20] [21] [22] For malignant polyclonal or monoclonal PTLD with CD20 expression, the anti-CD20 monoclonal antibody rituximab is often utilized. 20 Use of rituximab alone has been shown to achieve 44.2% effectiveness in 1 clinical trial. 23 Further treatment of malignant PTLD includes the use of chemotherapy agents with steroids, cyclophosphamide, doxorubicin or daunorubicin, vincristine, prednisone (CHOP), with the addition of rituximab for CD20 + PTLD (R-CHOP), 17, 20 which has reported to achieve complete remission in 40%-60% of patients. 20, 22, 24 Less commonly used chemotherapy regimens for malignant T-Cell PTLD include separate courses of cyclophosphamide, vincristine, doxorubicin, and dexamethasone, followed by methotrexate and cytarabine (HyperCVAD) or the use of etoposide, prednisone, vincristine, cyclophosphamide, and hydroxydaunorubicin (EPOCH) chemotherapy. 38, 39 Given the wide range of characteristics of PTLD and treatment regimens presented here, it is suggestive that investigation of specific PTLD characteristics will be beneficial. With relatively higher incidence rates higher than other solid organ transplants, studies assessing survival after PTLD onset in lung transplant recipients appear warranted. The primary objective of this study was to identify disease and patient characteristics associated with PTLD survival in LTRs.
| ME THODS

| Data source and search strategy
Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a literature search was performed in consultation with a medical reference librarian in July 2016 through MEDLINE, EMBASE, SCOPUS, and Cochrane databases for English, human studies, with no other filters set.
The search terms "(ptld AND post transplant lymphoproliferative disease) AND (lung transplant)" were applied to all 4 databases to search for the primary outcome of death associated to PTLD in lung transplant recipients. This search term includes both "lymphoproliferative disease" and lymphoproliferative disorder" in the MeSH terms.
| Study selection criteria
All studies were included from the initial search and were evaluated for exclusion. Four researchers (J.C., C.M., C.I., C.E.) convened to determine exclusion of studies if they (i) were duplicates of each other, (ii) were nonlung studies, (iii) abstracts, (iv 
| Data extraction
| Statistical analysis
Categorical characteristics were analyzed for odds ratio using a 2 × 2 contingency For both categorical and continuous characteristics, the degree of heterogeneity was evaluated with the I 2 statistic and analyzed by the random effects model. Using the suggestion of identifying and measuring heterogeneity for systematic reviews by Cochrane reviews, 35 chi-squared tests were analyzed by forest plot, with a Pvalue cutoff set to .10 to determine significance. Calculated I 2 values
were also interpreted as recommended by Cochrane reviews 46 as follows-0%-40%: might not be important; 30%-60%: may represent moderate heterogeneity; 50%-90%: may represent substantial heterogeneity; 75%-100%: considerable heterogeneity.
| RE SULTS
Figure 1 details a flowchart of the basis that studies were excluded.
Of the 14 studies, 3, 16, 17, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] a total of 164 PTLD lung transplant patients were analyzed for outcomes and characteristics data. Table 1 shows studies that provided treatments and treatment outcomes for PTLD in LTR. Of the data extracted and compiled from the studies, characteristics of early and late onset PTLD, time from transplant to PTLD onset, morphology, nodal involvement, age, and type of lung transplant were analyzable.
Thirteen studies were retrospective cohort studies that analyzed patient charts from hospital records, 3, 16, 17, [25] [26] [27] [28] [29] [30] [32] [33] [34] [35] and 1 study was a prospective cohort study that analyzed the use of rituximab as first-line treatment. 31 One study was a multi-center study over 3 centers in 3 countries, 32 while the remaining 13 were single studies. Eight of the studies were international, [25] [26] [27] [29] [30] [31] [32] [33] [34] conducted in 11 different countries, with 3 of the studies conducted in the USA.
Characteristics of data extracted from each study are summarized in Table 1 .
A total of 6 studies analyzed lung transplant (LT) type (single or bilateral). The analysis included a total of 64 patients with a pOR of 7.674 (95%CI: 1.983, 29.698; P = .003; I 2 = 0.0%) that showed greater odds of death from PTLD for single LT patients than bilateral LT patients ( Figure 2 ). Whether patients experienced early or late PTLD accounted for 3 studies, no statistical difference was found (Table 2) . Twelve studies included time to PTLD in their results, and no statistical difference was found (Table 2) . PTLD morphologies were reported in 6 studies, and no statistical difference was found (Table 2) . Nodal involvement was reported in 10 of the studies analyzed, and no statistical difference was found ( Table 3 . The authors recognized that the disparity for higher incidence of malignancies for LTRs may be the result of the higher intensity of immunosuppression and the large amount of lymphoid tissue within the lung graft, compared to other organs.
To our knowledge, this is the first meta-analysis of lung transplant PTLD patient characteristics and death. Our main finding was that single-lung transplant recipients who developed PTLD were at a statistically significant increased risk of death. This finding is in line with current literature supporting bilateral lung transplantation's association with better outcomes. [41] [42] [43] [44] 45 No study to our knowledge has directly analyzed the characteristics of bi- at 1 single center for heart and lung transplantation that identified overall survival prognostic factors of bone marrow involvement (HR 6.75, P < .001), hypoalbuminemia (HR 3.18, P = .006), and complete response within 1-3 months (HR 0.08, P < .001). 48 The ISHLT has also reported that patients who receive bilateral lung transplants tend to be younger (<65) and are less subjected to comorbidities and post-transplant complications, since releasing registry reports in 1998. 44 This suggests that age may have a correlation to PTLD outcomes in LTRs; however, our analysis did not show this, which may be attributed to our older patient cohort (Mean = 46 years; Median 52 years).
Several studies have concluded that patients who undergo bilateral transplant have more favorable outcomes than single-lung transplant recipients. [41] [42] [43] [44] There remains debate regarding whether bilateral transplantation has better outcomes in general, as studies have been published supporting the fact that single-lung transplantation may have comparable outcomes to bilateral lung transplantation. 42, 46 As a result, our findings further suggest the fact that larger controlled studies are needed to determine specific factors for favoring the outcomes of single or bilateral lung transplantation.
Our study had several limitations. Given the relatively rare occurrence of PTLD in lung transplant patients, there simply are not many studies analyzing characteristics of this small and specific patient population. As a result, instead of calculating a minimum patient population to give trial power to detect a difference, we assumed our small sample size was limited in power and ability to detect a difference in all but one of our outcomes. However, although this outcome did have an I 2 statistic of 0.0% suggestive of complete homogeneity, as with 3 other outcomes studied, the large confidence interval suspects that some level of bias is taking place and the credibility of the I 2 statistic is decreased. The exclusion of 50 single case studies is notable as collectively, the inclusion of these studies may have a significant contribution to our findings. The degree of inconsistencies of characteristics reported for these single case studies made their inclusion very challenging and would have added significant heterogeneity to the findings.
Furthermore, given that all but one of our studies were retrospective analyses, selection bias and the quality of evidence is ques- TA B L E 3 (Continued)
had a 77% chance of response to RI alone. 51 This suggests that our findings from this analysis may be possibly confounded by other factors described by Tsai et al. It is difficult, however, to associate these factors in LTRs, as our analysis did not find a significant difference in any factors, except type of LT. Furthermore, of the 148 patients analyzed, only 27 were LTRs with the majority (40%) being kidney transplants, making it difficult to definitively translate these findings specifically to lung transplantation.
In conclusion, our findings that bilateral lung transplantation is associated with a significantly lower risk of death from PTLD complications than single-lung transplantation adds to the body of literature that perceives bilateral lung transplantation to be associated with more favorable outcomes. Further conclusions are difficult to draw given the current state of the PTLD literature in LTRs.
Accordingly, we call on our colleagues to report their single and multicenter findings of PTLD in LTRs as more research is required to define risk and treatment outcomes in a robust way.
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